Bacil Pharma (524516) Q2 25/26 earnings summary

Executive summary

• Unaudited financial results for the quarter and half-year ended September 30, 2025, were approved by the board and reviewed by statutory auditors.

• The company operates a single business segment, making segment reporting inapplicable.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹5.49 lakh, down from ₹100.25 lakh in the previous quarter and ₹56.04 lakh in Q2 FY25.

• Net profit for Q2 FY26 stood at ₹0.92 lakh, compared to ₹73.20 lakh in Q1 FY26 and ₹26.37 lakh in Q2 FY25.

• Total expenses for Q2 FY26 were ₹3.65 lakh, significantly lower than ₹10.89 lakh in Q1 FY26.

• Basic and diluted EPS for Q2 FY26 was ₹0.01, compared to ₹0.48 in Q1 FY26.

Outlook and guidance

• No explicit forward-looking guidance provided; auditor's report highlights significant uncertainties and lack of documentation.